Marshall Wace LLP Makes New $1.11 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Marshall Wace LLP acquired a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 95,339 shares of the company's stock, valued at approximately $1,112,000. Marshall Wace LLP owned 0.09% of Intellia Therapeutics as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in NTLA. Barclays PLC increased its stake in Intellia Therapeutics by 17.7% during the 3rd quarter. Barclays PLC now owns 292,795 shares of the company's stock worth $6,017,000 after acquiring an additional 44,022 shares during the period. Virtu Financial LLC bought a new stake in Intellia Therapeutics during the third quarter worth about $417,000. Franklin Resources Inc. grew its stake in Intellia Therapeutics by 10.3% during the third quarter. Franklin Resources Inc. now owns 16,405 shares of the company's stock worth $320,000 after buying an additional 1,538 shares in the last quarter. Green Alpha Advisors LLC bought a new position in Intellia Therapeutics in the 4th quarter valued at about $138,000. Finally, AdvisorNet Financial Inc raised its position in shares of Intellia Therapeutics by 96.4% in the 4th quarter. AdvisorNet Financial Inc now owns 10,085 shares of the company's stock valued at $118,000 after buying an additional 4,950 shares in the last quarter. Institutional investors and hedge funds own 88.77% of the company's stock.

Intellia Therapeutics Stock Up 2.3 %

Intellia Therapeutics stock traded up $0.20 during mid-day trading on Friday, hitting $8.84. 3,461,561 shares of the stock were exchanged, compared to its average volume of 2,422,444. The firm's fifty day simple moving average is $8.35 and its two-hundred day simple moving average is $11.45. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The stock has a market capitalization of $915.67 million, a price-to-earnings ratio of -1.62 and a beta of 2.33.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on NTLA. Wedbush reissued a "neutral" rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Chardan Capital decreased their price target on Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating on the stock in a research note on Friday, February 28th. Barclays dropped their price objective on Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Truist Financial decreased their target price on Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company dropped their target price on shares of Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Two investment analysts have rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, Intellia Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $36.68.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.